BIBAN
13.3.2023 18:59:40 CET | Business Wire | Press release
After four days of fierce competition, with 100 up-and-coming startups representing 53 countries, one has emerged the victor of the Entrepreneurship World Cup (EWC). White Helmet, a company that provides a platform to manage and monitor construction operations remotely, from anywhere and at any time, returns home with a US$300,000 share of the $1 million prize pot.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230313005706/en/
The EWC winners and finalists at Biban 2023 came from around the world to compete (Photo: AETOSWire)
Co-hosted by the Global Entrepreneurship Network (GEN) and Monsha’at – the Small and Medium Enterprises General Authority in Saudi Arabia – EWC is one of the world’s largest pitch competitions and startup support programs.
Since launching in 2019, EWC has engaged more than 400,000 entrepreneurs from 200 countries and connected founders with over US$4 million in cash prizes and another US$266 million worth of perks and free support and services.
The competition attracted over 30,000 founders, with 100 of the top-performing countries invited to pitch to a panel of international judges at the Global Finals after several qualifying rounds. The final pitches were held at Biban 2023, the largest forum for entrepreneurs and small-to-medium-sized enterprises in Saudi Arabia.
Providing over 105,000 participants a platform to advance entrepreneurship in the Kingdom, the forum’s theme this year is “Attract-Connect-Achieve”.
In addition to the grand $300,000 prize, 10 startups from diverse countries received cash prizes of $25,000-$200,000 to take their innovative solutions to the next level.
Sami Ibrahim Alhussaini, Governor of Monsha’at, said: “Saudi innovation and ingenuity has driven the advancement of the Kingdom’s startup and SME ecosystem forward over the past years. We are proud to have a Saudi company named the champion of the latest edition of the EWC. We hope this win will inspire more of our people to take that step forward and realize their entrepreneurial ambitions.”
“These founders and their companies are disrupting their industries and testing big ideas with potential to transform our world,” said Jonathan Ortmans, president of GEN. “GEN is proud to co-host the Entrepreneurship World Cup for the fourth year, giving promising companies the opportunity to connect to global markets and investment.”
The Entrepreneurship World Cup is supported by several national and global partners including One Valley, The Global Education and Leadership Foundation (tGELF), Entrepreneurs’ Organization, King Abdullah University for Science and Technology and Startup Genome. The Misk Foundation is a founding partner.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230313005706/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FlexTrade Expands Portfolio Risk and Analytics Capabilities Through Strategic Partnership with Portx13.7.2026 15:30:00 CEST | Press release
The collaboration expands FlexTrade’s front-office risk analytics offering, connecting portfolio construction, risk insight, and trading decisions in a unified buy-side workflow. FlexTrade Systems (@FlexTrade), a global leader in multi-asset execution and order management systems, and Portx, an advanced portfolio construction and analytics provider, today announced the integration of Portx’sreal-time portfolio construction, optimization, and risk analytics capabilities into FlexTrade’s integrated buy-side order and execution management system (OEMS), FlexONE. The partnership comes as buy-side firms place greater emphasis on real-time risk management across increasingly complex portfolios, advanced hedging strategies, and supporting operating models. For hedge funds and institutional asset managers, particularly those running multi-strategy or multi-asset approaches, the ability to assess portfolio risk, review pro forma exposures, and act on those insights within the order and executio
Xsolla Connect Returns to Brighton13.7.2026 15:22:00 CEST | Press release
Connecting The UK Game Development Community For Networking And Insights During Develop:Brighton Xsolla, a global video game commerce company, today announced the launch of an exclusive networking event for the UK game development community, Xsolla Connect, taking place with Develop:Brighton 2026 on July 15, 2026. Designed to bring together independent and mid-tier developers, publishers, investors, and industry professionals, the event will offer a focused evening of meaningful connections and actionable insights at one of the UK’s most important annual games gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713748542/en/ Graphic: Xsolla Develop:Brighton has long served as a cornerstone of the European video games industry, drawing developers, publishers, investors, and studio leaders from across the UK and beyond to share knowledge, explore opportunities, and forge lasting business relationships. Xsolla’s event
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 14:32:00 CEST | Press release
Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company'
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 14:00:00 CEST | Press release
Integrated subsea production system and local capabilities enable accelerated deepwater development Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, um
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 14:00:00 CEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
